550
Participants
Start Date
December 31, 2014
Primary Completion Date
July 31, 2034
Study Completion Date
December 31, 2034
Blood draws
Tenofovir Alafenamide
25 mg tablet, once a day by mouth.
Knowledge Index Questionnaire
Liver transient elastography (FibroScan)
Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
Liver Biopsy
40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
RECRUITING
Institute of Human Virology, University of Maryland School of Medicine, Baltimore
RECRUITING
Dr Huong Dang, Medical Practice, Falls Church
University of Maryland, Baltimore
OTHER